NNMT

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

Retrieved on: 
Tuesday, June 8, 2021
Medical specialties, Hepatitis, Anatomy, Clinical medicine, Steatohepatitis, Fatty liver disease, Non-alcoholic fatty liver disease, Liver disease, Aramchol, NNMT

WEST CONSHOHOCKEN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences:

Key Points: 
  • WEST CONSHOHOCKEN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences:
    Fireside chat at 9:40 a.m.
  • ET on Thursday, June 10, 2021
    Fireside chat at 3:30 pm ET on Wednesday, June 16, 2021
    The presentation will be webcast live and can be accessed in the Investor Relations section of the Madrigal website and will be available for replay for 90 days.
  • https://www.madrigalpharma.com/newsroom/presentations/
    Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.
  • Madrigals lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)- selective agonist that is in currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits across a broad spectrum of NASH (non-alcoholic steatohepatitis) and NAFLD (non-alcoholic fatty liver disease) patients.

 Brightseed Announces Preclinical Data For Phytonutrients Targeting Liver and Metabolic Health

Retrieved on: 
Tuesday, January 5, 2021
Biotechnology, Health, Data management, Fitness & Nutrition, Technology, Medical specialties, Anatomy, Hepatitis, Non-alcoholic fatty liver disease, Clinical medicine, Fatty liver disease, Liver disease, Liver, Alcoholic liver disease, Diabetes, Steatohepatitis, NNMT

that maps the hidden world of phytonutrients and their impact on human health, today announced preclinical data from its first major discovery targeting liver and metabolic health.

Key Points: 
  • that maps the hidden world of phytonutrients and their impact on human health, today announced preclinical data from its first major discovery targeting liver and metabolic health.
  • Researchers determined that these compounds acted through a novel biological mechanism governing the accumulation and clearance of liver fat.
  • These preclinical findings provide compelling data for a natural solution that activates a specific human biological target to address an emerging global health crisis.
  • The liver is the bodys primary metabolic organ and a healthy liver helps avoid metabolic conditions such as type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD).